SMMT:NSD-Summit Therapeutics plc (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 7.24

Change

+0.35 (+5.08)%

Market Cap

USD 0.14B

Volume

1.97M

Analyst Target

USD 4.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Summit Therapeutics PLC is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.76 (+0.39%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-1.77 (-0.17%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-1.54 (-0.57%)

USD 34.86B
ARGX argenx NV ADR

-13.04 (-2.40%)

USD 32.89B
MRNA Moderna Inc

-0.87 (-1.42%)

USD 25.27B
BGNE BeiGene Ltd

+12.40 (+5.31%)

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

+5.86 (+1.67%)

USD 15.95B
PCVX Vaxcyte Inc

+0.21 (+0.19%)

USD 14.00B
BMRN Biomarin Pharmaceutical Inc

+1.35 (+1.98%)

USD 13.44B

ETFs Containing SMMT

BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

+0.49 (+1.13%)

USD 0.01B
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

+0.44 (+1.13%)

USD 0.01B
FYX First Trust Small Cap Cor.. 0.00 % 0.63 %

+1.09 (+1.13%)

USD 0.91B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 177.39% 97% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 177.39% 97% N/A 98% N/A
Trailing 12 Months  
Capital Gain 231.35% 98% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 231.35% 98% N/A 99% N/A
Trailing 5 Years  
Capital Gain 461.24% 96% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 461.24% 96% N/A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 64.01% 88% B+ 93% A
Dividend Return 64.01% 88% B+ 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 115.60% 22% F 13% F
Risk Adjusted Return 55.38% 95% A 82% B
Market Capitalization 0.14B 95% A 89% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 20.53 28% 44%
Price/Book Ratio 33.10 4% 3%
Price / Cash Flow Ratio -71.33 100% 96%
Price/Free Cash Flow Ratio -4.18 71% 75%
Management Effectiveness  
Return on Equity -130.59% 33% 16%
Return on Invested Capital -21.69% 77% 33%
Return on Assets -33.27% 45% 16%
Debt to Equity Ratio 128.71% 15% 17%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector